Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
The Schmooze

Sarah Jessica Parker Blasts EpiPen Maker For Jacking Up Prices

Sarah Jessica Parker came out on Instagram today officially announcing the end of her relationship with Mylan, the company that produces the EpiPen. SJP—whose son, James Wilkie, uses an EpiPen for his peanut allergy—had been involved in an initiative with Mylan to raise awareness for anaphylaxis, potentially life-threatening allergic reactions that the EpiPen (and the medicine it delivers, epinephrine) are designed to combat.

Parker stated that her decision to cut ties with Mylan is a “direct result” of the company’s recent price hikes regarding the cost of the EpiPen—and, looking at the numbers, she has a significant point. When Mylan started selling the EpiPen in 2007, it cost $57. Since then, the price has increased drastically each year, culminating in the recent announcement that the EpiPen would now be sold for over $500. That’s a price hike of over 400% in the span of nine years.

In her statement, SJP rightly accused the company of making the EpiPen cost prohibitive to “countless people”. She joined a large number of parents, educators, doctors, and general health and safety advocates who have been calling out Mylan for their actions, and it looks as if they may have had something of an impact. In a statement given to People Magazine today, Mylan said it would eliminate out-of-pocket expenses for uninsured and under-insured patients, and cover up to $300 of out-of-pocket costs at pharmacies.

It’s still not clear how much of that promise the company will actually fulfill, but good on SJP (and the many other people who raised their voices) for making a positive change. Because seriously, $500 for an EpiPen? That’s ridiculous. You go, girl.

Read SJP’s full post below:

A photo posted by SJP (@sarahjessicaparker) on

A message from our Publisher & CEO Rachel Fishman Feddersen

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

We’ve set a goal to raise $260,000 by December 31. That’s an ambitious goal, but one that will give us the resources we need to invest in the high quality news, opinion, analysis and cultural coverage that isn’t available anywhere else.

If you feel inspired to make an impact, now is the time to give something back. Join us as a member at your most generous level.

—  Rachel Fishman Feddersen, Publisher and CEO

With your support, we’ll be ready for whatever 2025 brings.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.